Link Biologics strengthens IP position for Link_TSG6 with US patent Notice of Allowance and University of Manchester IP assignment

·         Secures long‑term ownership and protection of Link_TSG6, strengthening its global IP position in key markets

·         De‑risks development and enhances long‑term value, supporting advancement towards clinical development

London, UK – 6 May 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies that have a unique combination of anti-inflammatory, tissue-protective and tissue-reparative properties, today announces the successful assignment of intellectual property (IP) from the University of Manchester alongside a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering Link_TSG6  for the treatment of Dry Eye Disease (DED). 

Together, these significantly strengthen the Company’s global IP estate around Link_TSG6, for the treatment of DED, supporting long-term value creation.

Link_TSG6 is a protein biologic that modulates multiple aspects of disease by harnessing the protective biology of the TSG-6 protein. The Company’s lead programme is in DED, which has progressed through key manufacturing, formulation and regulatory milestones, including GMP production at clinical scale, generation of PK and BD data across multiple species, and completion of 4-week GLP toxicology in two species. The programme is planned to advance into a Phase 1/2 clinical trial in the first half of 2027, which has been validated by the FDA as Phase 3-enabling.

Reuben Dawkins, Chief Executive Officer of Link Biologics, commented: “Securing this IP protection underpins the long‑term value and development pathway of Link_TSG6, for the treatment of Dry Eye Disease. With clear ownership and protection in major markets, including Europe, Japan, and now the US, we are well positioned to advance our lead asset towards clinical development and move closer to bringing a novel treatment to patients underserved by current standards of care.”

Full assignment University of Manchester IP

Under the terms of the agreement, Link Biologics has acquired full ownership of key patent rights for Link_TSG6 in the treatment of DED originally developed at the University of Manchester. This marks an important milestone in the Company’s evolution from university spin‑out to independent biotech.

US patent Notice of Allowance

In parallel, the USPTO has issued a Notice of Allowance for a patent covering Link_TSG6, which, once granted, is expected to provide patent protection in the United States until at least 2039.

This patent further reinforces Link’s growing patent portfolio for Link_TSG6 and complements existing patents granted in Europe and Japan.